Overall, these results indicate that anti-DLL1 Dl1.72 can impair oncogenic features of ER+ BC MCF-7 cells, such as cell proliferation, migration and the maintenance of the BCSC subpopulation, possibly through SOX9 modulation. This evidence concerns the gene DLL1 and breast cancer.